STOCK TITAN
  1. Home
  2. Sec-filings
  3. RVPH
  4. [25-NSE] REVIVA PHARMACEUTICALS HOLDINGS, INC. SEC Filing

Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) — Files Form 25 to remove Common Stock from Nasdaq listing

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
25-NSE

Rhea-AI Filing Summary

Reviva Pharmaceuticals Holdings, Inc. notified that its Common Stock will be removed from listing and/or registration on the Nasdaq Stock Market LLC under Form 25; Nasdaq certifies it has complied with 17 CFR 240.12d2-2 and the issuer has complied with Exchange rules governing voluntary withdrawal.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Nasdaq and the issuer completed the procedural steps to delist Reviva's common stock under the cited SEC rule.

Nasdaq submitted a Form 25 notifying removal of Common Stock for Reviva Pharmaceuticals Holdings, Inc. and cites compliance with 17 CFR 240.12d2-2. The filing is procedural: it documents exchange action and issuer concurrence rather than financial measures.

Market implications depend on subsequent actions by the company or transfer of listing venue; the filing itself contains no offering, proceeds, or numeric holdings changes.

Commission File Number 001-38634 Commission File Number listed on the Form 25 cover
Issuer telephone number (408) 501-8881 Telephone number of Issuer's principal executive offices
Issuer zip code 95014 Zip code in issuer address at 19925 Stevens Creek Blvd., Suite 100, Cupertino, California
Form 25 regulatory
"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING"
A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.
withdrawal of registration regulatory
"voluntary withdrawal of the class of securities from listing and registration"
17 CFR 240.12d2-2 regulatory
"Pursuant to 17 CFR 240.12d2-2(b) the Exchange has complied"
A U.S. Securities and Exchange Commission rule that describes the conditions and procedural steps for a security to be removed from public registration or reporting under the Securities Exchange Act of 1934. For investors, it matters because it explains when a company’s shares can stop being subject to regular disclosure and exchange listing rules — similar to knowing when a publicly tracked product will be discontinued and no longer send updates, which affects transparency and liquidity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

FAQ

What action does the Form 25 for RVPH report?
It reports removal of RVPH Common Stock from Nasdaq listing/registration. The filing states Nasdaq followed 17 CFR 240.12d2-2 and that the issuer complied with Exchange rules for voluntary withdrawal.

Who certified compliance on the Form 25 for RVPH?
Nasdaq Stock Market LLC certified compliance. The notice is signed on Nasdaq's behalf by Aravind Menon, Hearings Advisor, attesting to adherence to the cited exchange and SEC procedures.

Does the Form 25 state any proceeds, share counts, or exchange transfer details?
No monetary amounts, share counts, or proceeds are disclosed. The filing is a procedural withdrawal notice citing rule compliance and does not provide financial figures or a new listing venue.

What class of security is being removed according to the Form 25?
The filing specifies the issuer's Common Stock. The Form 25 lists the security class as Common Stock for Reviva Pharmaceuticals Holdings, Inc.
UNITED STATES
OMB APPROVAL
OMB Number: 3235-0080
Expires: March 31, 2018
Estimated average burden
hours per response: 1.7
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-38634
Issuer: REVIVA PHARMACEUTICALS HOLDINGS, INC.
Exchange: Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 19925 Stevens Creek Blvd., Suite 100
Cupertino CALIFORNIA 95014
Telephone number: (408) 501-8881
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common Stock
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
17 CFR 240.12d2-2(a)(1)
17 CFR 240.12d2-2(a)(2)
17 CFR 240.12d2-2(a)(3)
17 CFR 240.12d2-2(a)(4)
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2026-07-10 By Aravind Menon Hearings Advisor
Date Name Title
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR